Key Finding:
- In colorectal cancer patients, median overall survival and median overall survival in response to immune checkpoint inhibition is longer in patients with intact MLH1 and PMS2 and co-loss of MSH2 and MSH6 (MutS) versus co-loss of MLH1 and PMS2 and intact MSH2 and MSH6 (MutL).